CEO Paul LaViolette received total compensation of approximately $7.4 million in his first year as CEO, consisting almost entirely of stock option awards ($6.7 million reported value) with performance-based and market-cap-based vesting conditions tied to ambitious milestones ($3B–$9B market cap with substantial revenue and margin thresholds) — this structure is heavily weighted toward variable, long-term, performance-linked pay, which is consistent with good compensation design. The base salary of $708,523 represents only about 10% of total reported compensation, and no cash bonus was awarded for 2025 because the Compensation Committee concluded that 2025 corporate objectives were not achieved, demonstrating genuine pay-for-performance discipline. The company's 3-year stock return of approximately 293% significantly outperforms the XBI (SPDR S&P Biotech ETF) benchmark applicable to this biotech company, providing strong pay-for-performance alignment for the incentive component.

Non-audit fees (audit-related fees of $205,000 plus all other fees of $64,000 = $269,000) represent approximately 31% of audit fees ($860,000), which is well below the 50% threshold that would raise independence concerns; Deloitte & Touche is a Big 4 firm appropriate for a company of this size; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire, but this is noted as a minor negative; no material restatements are disclosed.